South Korea's SK Biopharmaceuticals Co., Ltd. (326030.KS) reported Friday lower profit in the fourth quarter, while operating income increased with higher sales.
In South Korea, the shares were trading 4.4 percent lower, at 106,600 won.
In the quarter, net income attributable to shareholders of parent company dropped 28.2 percent to 136.59 billion won from 190.12 billion won a year ago.
Operating income, however, grew 13.8 percent to 46.28 billion won from last year's 40.65 billion won.
Sales climbed 19.2 percent to 194.36 billion won from 163.03 billion won a year earlier.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.